Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any autosomal dominant nocturnal frontal lobe epilepsy in which the cause of the disease is a mutation in the CHRNA4 gene.
Features include sometimes findings: Intellectual disability. 3 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 3 | Seizure, Focal-onset seizure, Intellectual disability |
Age of onset: childhood.
Autosomal dominant sleep-related hypermotor (hyperkinetic) epilepsy (ADSHE) is characterized by clusters of nocturnal motor seizures with a range of manifestations.
Table 2.
Autosomal Dominant Sleep-Related Hypermotor (Hyperkinetic) Epilepsy: Frequency of Select Features
Feature | % of Persons w/Feature | Comment
Sleep-related seizures | 100% | • Focal motor seizures w/vigorous hyperkinetic or asymmetric tonic/dystonic features1
May occur at any stage during sleep, but typically cluster in non-REM sleep
Some persons experience daytime seizures.
EEG abnormalities | • 10%-50% while awake1,2
50% during sleep1,2
| • Interictal epileptiform abnormalities over the frontal areas during sleep.
Ictal EEG may show evolving sharp- or spike-and-wave, rhythmic slow activity, or diffuse flattening.
Source: GeneReviews — "Autosomal Dominant Sleep-Related Hypermotor (Hyperkinetic) Epilepsy"
CHRNA4 encodes cholinergic receptor nicotinic alpha 4 subunit (627 aa). Component of neuronal acetylcholine receptors (nAChRs) that function as pentameric, ligand-gated cation channels with high calcium permeability among other activities. Highest expression in Liver (24.9 TPM) and Brain Frontal Cortex BA9 (8.3 TPM).
Autosomal dominant nocturnal frontal lobe epilepsy 1 is associated with mutations in the CHRNA4 gene on chromosome 20.
CHRNA4 is classified as a druggable target (Dna Repair, Druggable Genome, External Side Of Plasma Membrane, and Ion Channel categories) with score 2.2.
suggested that certain pathogenic variants in nicotinic acetylcholine receptor (nAChR) genes (CHRNA2, CHRNA4, CHRNB2) may be associated with an increased risk of unfavorable outcomes. Individuals with the CHRNA4 pathogenic variant tend to have early onset of epilepsy and less favorable cognitive function. They respond only partially to carbamazepine and are more responsive to zonisamide . The CHRNB2 pathogenic variant was associated with clinically relevant deficits in cognitive function. Affected members from two unrelated families with the variant show normal or low-average intellect with moderate-to-significant verbal memory deficits . Marked intrafamilial variation in severity is seen in ADSHE; the reasons for this are not well understood.
Source: GeneReviews — "Autosomal Dominant Sleep-Related Hypermotor (Hyperkinetic) Epilepsy"
The penetrance of ADSHE is estimated to be 70%. KCNT1-related ADSHE demonstrates complete penetrance compared to 60%-80% in nAChR-related ADSHE.
Source: GeneReviews — "Autosomal Dominant Sleep-Related Hypermotor (Hyperkinetic) Epilepsy"
The International League Against Epilepsy (ILAE) has proposed diagnostic criteria for sleep-related hypermotor (hyperkinetic) epilepsy (SHE) , which consist of three groups of criteria. Mandatory feature. Brief focal motor seizure with hyperkinetic or asymmetric tonic/dystonic features occurring predominantly during sleep Alerts. Features that are absent in most cases but rarely can be seen. Their presence should result in caution in diagnosing the syndrome and consideration of other conditions. They include the following:
Source: GeneReviews — "Autosomal Dominant Sleep-Related Hypermotor (Hyperkinetic) Epilepsy"
The differential diagnosis of autosomal dominant sleep-related hypermotor (hyperkinetic) epilepsy (ADSHE) includes autosomal recessive SHE caused by biallelic pathogenic variants in PRIMA1 (reported in only one family to date ) and other conditions of varied etiology, including the following:
Source: GeneReviews — "Autosomal Dominant Sleep-Related Hypermotor (Hyperkinetic) Epilepsy"
Genetic testing for CHRNA4 is available. Testing is considered confirmatory for diagnosis.
No approved treatments are currently available for autosomal dominant nocturnal frontal lobe epilepsy 1. The disease remains an area of unmet medical need.
No clinical practice guidelines regarding the management for autosomal dominant sleep-related hypermotor (hyperkinetic) epilepsy (ADSHE) have been published. Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with ADSHE, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 5. Recommended Evaluations Following Initial Diagnosis in Individuals with Autosomal Dominant Sleep-Related Hypermotor (Hyperkinetic) Epilepsy
System/Concern | Evaluation | Comment |
|---|---|---|
Neurologic | Assessment by neurologist w/eval of suspected seizures as indicated | To incl EEG high-resolution brain MRI to evaluate for focal brain malformations, if suspected based on seizure semiology |
Development | Assessment by developmental specialist | To incl motor, adaptive, cognitive, speech-language eval; Eval for early intervention/ special education |
Psychiatric | Assessment by psychiatrist | For any psychiatric comorbidities or complications |
Genetic counseling | By genetics professionals1 | To obtain a pedigree inform affected persons their families re nature, MOI, implications of ADSHE to facilitate medical personal decision making Family support resources |
Treatment of Manifestations in Individuals with Autosomal Dominant Sleep-Related Hypermotor (Hyperkinetic) Epilepsy Manifestation/Concern |
Source: GeneReviews — "Autosomal Dominant Sleep-Related Hypermotor (Hyperkinetic) Epilepsy"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Autosomal Dominant Sleep-Related Hypermotor (Hyperkinetic) Epilepsy"
View trials for autosomal dominant nocturnal frontal lobe epilepsy 1
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended. Table 7. Recommended Surveillance for Individuals with Autosomal Dominant Sleep-related Hypermotor Epilepsy (ADSHE)
System/Concern | Evaluation | Frequency |
|---|---|---|
Development | Monitor developmental progress educational needs. | If applicable Eval by developmental pediatrician or developmental specialist |
Psychiatric | Eval by psychiatrist for any psychiatric comorbidities | If applicable |
Family/Community | Assess family need for social work support (e.g., palliative/respite care, other local resources), care coordination, or follow-up genetic counseling if new questions arise (e.g., family planning). | At each visit |
Source: GeneReviews — "Autosomal Dominant Sleep-Related Hypermotor (Hyperkinetic) Epilepsy"
No clinical trials have been registered for autosomal dominant nocturnal frontal lobe epilepsy 1.
4 publications have been identified in PubMed for autosomal dominant nocturnal frontal lobe epilepsy 1. Research spans Case Report / Case Series (50%), Review / Meta-Analysis (25%), and Basic Science / Preclinical (25%).
Makhmetov S (2025). [PMID: 39834405](https://pubmed.ncbi.nlm.nih.gov/39834405/). *Heliyon*. [Case Report / Case Series]
Wang R (2025). [PMID: 40161404](https://pubmed.ncbi.nlm.nih.gov/40161404/). *Sleep Adv*. [Basic Science / Preclinical]
Bisulli F (2025). [PMID: 40085429](https://pubmed.ncbi.nlm.nih.gov/40085429/). *Epilepsia*. [Review / Meta-Analysis]
Mulkerrin G (2024). [PMID: 38983576](https://pubmed.ncbi.nlm.nih.gov/38983576/). *Epilepsy Behav Rep*. [Case Report / Case Series]
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 5:34 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Treatment |
Considerations/Other |
Epilepsy | Standardized treatment w/ASM by epileptologist or experienced neurologist | Many ASM may be effective; In about 70% of persons w/ADSHE, carbamazepine is assoc w/remission of seizures, often w/relatively low doses. However, persons w/ADSHE assoc w/CHRNA4 pathogenic variant respond only partially to carbamazepine are more responsive to zonisamide. |
Developmental delay/ Intellectual disability | See . | — |
Psychiatric issues | Standardized treatment by psychiatrist | Family/Community |